Drug intelligence / Profile preview

GC3114B

Development stage: Preclinical
Lead developer: GC Biopharma
Modality: Vaccines & Immunotherapeutics

Overview

**GC3114B** is a GC Biopharma preclinical trivalent influenza vaccine candidate intended to prevent influenza by eliciting protective immune responses against the influenza-virus components included in the vaccine. The company pipeline identifies the program as a vaccine for trivalent flu and lists it at the preclinical stage; its specific vaccine platform, strain composition, adjuvant, dosage form, and route of administration have not been publicly disclosed. ([gcbiopharma.com](https://www.gcbiopharma.com/eng/pipeline.do))

Targets

Flu (Influenza surface proteins)

Beyond the preview

Go deeper on GC3114B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GC3114B.

Explore the full profile